Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ETONthis companyEton Pharmaceuticals, Inc.	$59.09	-99.47×	17.4×	5.69×	107.83×	-174.2%	53.5%	0.1%	-5.8%	-17.6%	0.1%	2.2%	1.19×	1.19×	0.02×	1.57×	0.0%	7	12.98	3	B
DMACDiaMedica Therapeutics Inc.	$9.82	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
FENCFennec Pharmaceuticals Inc.	$10.65	-21.39×	6.28×	4.93×	-24.6×	-158.5%	91.6%	-14.2%	-21.8%	-27.8%	-10.7%	-5.7%	0×	4.93×	-3.05×	6.34×	0.0%	5	4.08	1	D+
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
LRMRLarimar Therapeutics, Inc.	$2.46	-1.68×	3.56×	0×	-1.19×	-55.3%	0.0%	0.0%	0.0%	-212.2%	-210.0%	-40.8%	0.05×	0.49×	0×	2.19×	0.0%	1	-2.84	2	C+
LXRXLexicon Pharmaceuticals, Inc.	$1.87	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
Peer median	—	-11.37×	6.28×	4.93×	-10.97×	-158.5%	91.6%	-14.2%	-21.8%	-58.4%	-28.7%	-7.8%	0.05×	0.47×	-3.05×	4.88×	0.0%	2	0.89	1	—